🇺🇸 LGND — Ligand Pharmaceuticals Incorporated
Salud Compra fuertePrecio actual
313,52 USD
Máx. histórico
322,75
4 días
Split 1603:1000 del 02/11/2022
Caída desde máximo
-2,86%
Rango 52 semanas
175,89 – 326,63
Variación hoy
+2,12%
Cierre anterior
307,02
Rango de hoy
309,46 – 317,76
Volumen hoy
195.564
Peor caída histórica
-93,34%
06/03/2000 → 19/11/2008
Recuperado en 2694 días
Volatilidad anualizada ⓘ
59,76%
- Nombre completo
- Ligand Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGM
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 47
- PER ⓘ
- 33,04 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 350,92 USD (puede no estar actualizado)
- Primera cotización
- 18/11/1992
- Precio actualizado
- hace 19 horas
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Fecha de pago | Importe por participación |
|---|---|
| 03/04/2007 | 9,3575 USD |
| Fecha | Ratio |
|---|---|
| 02/11/2022 | 1603:1000 |
| 19/11/2010 | 1:6 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/04/2023 | 73,36 | 73,80 | 69,96 | 71,58 | -2,69% | 5,23% | 130.200 |
| 31/03/2023 | 71,93 | 74,04 | 70,76 | 73,56 | +3,03% | 4,56% | 149.500 |
| 30/03/2023 | 72,72 | 73,00 | 69,70 | 71,40 | -0,98% | 4,54% | 128.100 |
| 29/03/2023 | 73,94 | 74,11 | 71,70 | 72,11 | -2,06% | 3,26% | 108.100 |
| 28/03/2023 | 70,26 | 74,03 | 70,13 | 73,63 | +4,72% | 5,55% | 151.700 |
| 27/03/2023 | 70,13 | 70,53 | 68,62 | 70,31 | +1,34% | 2,72% | 119.100 |
| 24/03/2023 | 67,93 | 70,10 | 67,46 | 69,38 | +0,90% | 3,89% | 89.800 |
| 23/03/2023 | 68,12 | 69,98 | 67,67 | 68,76 | +1,67% | 3,39% | 109.100 |
| 22/03/2023 | 70,99 | 71,35 | 67,44 | 67,63 | -4,99% | 5,51% | 126.500 |
| 21/03/2023 | 72,98 | 73,40 | 71,12 | 71,18 | -0,70% | 3,12% | 168.400 |
| 20/03/2023 | 72,57 | 73,95 | 70,76 | 71,68 | -0,67% | 4,40% | 118.400 |
| 17/03/2023 | 73,34 | 73,70 | 71,24 | 72,16 | -2,18% | 3,35% | 325.400 |
| 16/03/2023 | 70,42 | 73,96 | 69,74 | 73,77 | +3,02% | 5,99% | 102.700 |
| 15/03/2023 | 69,29 | 71,75 | 68,98 | 71,61 | +1,37% | 4,00% | 124.200 |
| 14/03/2023 | 69,02 | 70,78 | 68,81 | 70,64 | +4,90% | 2,85% | 119.800 |
| 13/03/2023 | 66,97 | 69,84 | 66,63 | 67,34 | -1,55% | 4,79% | 131.200 |
| 10/03/2023 | 71,66 | 71,69 | 68,00 | 68,40 | -5,11% | 5,15% | 127.700 |
| 09/03/2023 | 73,62 | 73,77 | 71,25 | 72,08 | -1,97% | 3,42% | 90.700 |
| 08/03/2023 | 72,85 | 73,53 | 72,22 | 73,53 | +1,32% | 1,80% | 82.400 |
| 07/03/2023 | 71,83 | 74,15 | 70,68 | 72,57 | +1,47% | 4,83% | 94.500 |
| 06/03/2023 | 76,36 | 77,75 | 69,86 | 71,52 | -7,21% | 10,33% | 183.300 |
| 03/03/2023 | 75,07 | 77,21 | 74,07 | 77,08 | +2,76% | 4,18% | 158.900 |
| 02/03/2023 | 73,82 | 75,60 | 72,35 | 75,01 | +1,47% | 4,40% | 123.900 |
| 01/03/2023 | 72,41 | 74,03 | 72,15 | 73,92 | +2,47% | 2,60% | 151.200 |
| 28/02/2023 | 73,32 | 74,57 | 71,87 | 72,14 | -1,23% | 3,68% | 134.100 |
| 27/02/2023 | 75,49 | 76,00 | 72,48 | 73,04 | -2,90% | 4,66% | 179.800 |
| 24/02/2023 | 74,42 | 75,26 | 72,68 | 75,22 | +0,17% | 3,47% | 242.800 |
| 23/02/2023 | 73,28 | 75,71 | 72,74 | 75,09 | +4,12% | 4,05% | 161.700 |
| 22/02/2023 | 71,00 | 73,09 | 70,77 | 72,12 | +1,75% | 3,27% | 150.900 |
| 21/02/2023 | 73,49 | 74,67 | 70,78 | 70,88 | -3,79% | 5,29% | 201.700 |